IP Library Granted Patent US 8,148,151
Granted Patent B2
US 8,148,151 · App. 12/303,104 · Granted Apr 3, 2012

Differentiation of primate pluripotent cells to hepatocyte-lineage cells

Assignees: Geron Corporation; The University Court of the University of Edinburgh
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,151
App. No.
12/303,104
Granted
Apr 3, 2012
Kind
B2
Abstract

Methods for differentiating primate pluripotent stem cells into hepatocyte-lineage cells are provided. In certain embodiments, the methods utilize sequential culturing of the primate pluripotent stem cells in certain growth factors to produce hepatocyte-lineage cells. In certain embodiments, the population of cells produced by the methods is further enriched for hepatocyte-lineage cells.

Claims (29)

1. A method of obtaining hepatocyte-lineage cells comprising sequentially culturing primate pluripotent stem cells in the following order:

culturing in a first culture medium comprising an Activin;

culturing in a second culture medium comprising at least one of an HGF polypeptide, an EGF polypeptide, and an OSM polypeptide; and

determining that the resultant population of cells contains at least 40% hepatocyte-lineage cells.

2. The method of claim 1 , wherein the primate pluripotent stem cells are human embryonic stem cells.

3. The method of claim 1 , wherein the Activin comprises an Activin peptide.

4. The method of claim 3 , wherein the Activin peptide comprises an active fragment of at least one of Activin A, Activin B, and Activin C.

5. The method of claim 1 , wherein the Activin comprises at least one of Activin A, Activin B, and Activin C.

6. The method of claim 5 , wherein the Activin is Activin A.

7. The method of claim 1 , wherein the HGF polypeptide is an active fragment of an HGF.

8. The method of claim 1 , wherein the HGF polypeptide is an HGF.

9. The method of claim 1 , wherein the EGF polypeptide is an active fragment of an EGF.

10. The method of claim 1 , wherein the EGF polypeptide is an EGF.

11. The method of claim 1 , wherein the OSM polypeptide is an active fragment of an OSM.

12. The method of claim 1 , wherein the OSM polypeptide is an OSM.

13. The method of claim 1 , wherein the first culture medium further comprises sodium butyrate.

14. The method of claim 1 , further comprising a step after step (a) and before step (b), comprising culturing in a third culture medium comprising DMSO.

15. The method of claim 1 , wherein the second culture medium comprises an HGF polypeptide and an EGF polypeptide.

16. The method of claim 15 , wherein the second culture medium further comprises dexamethasone.

17. The method of claim 15 , further comprising a step after step (b), comprising culturing in a fourth culture medium comprising an HGF polypeptide, an EGF polypeptide, and an OSM polypeptide.

18. The method of claim 1 , comprising characterizing the resultant population of cells as containing at least 60% hepatocyte-lineage cells.

19. The method of claim 1 , comprising characterizing the resultant population of cells as containing at least 80% hepatocyte-lineage cells.

20. The method of claim 1 , comprising characterizing the resultant population of cells as containing at least 90% hepatocyte-lineage cells.

21. A method of obtaining hepatocyte-lineage cells comprising sequentially culturing primate pluripotent stem cells in the following order:

culturing in a first culture medium comprising an Activin and sodium butyrate;

culturing in a second culture medium comprising DMSO;

culturing in a third culture medium comprising an HGF polypeptide, an EGF polypeptide, and dexamethasone;

culturing in a fourth culture medium comprising an HGF polypeptide, an EGF polypeptide, and an OSM polypeptide.

22. The method of claim 21 , further comprising a step after step (a) and before step (b) comprising culturing in a fifth culture medium comprising Activin and sodium butyrate, wherein the concentration of at least one of Activin and sodium butyrate is different than the concentration of the same factor in step (a).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031578/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2010
From: CUI, WEI; ZHAO, DEBIAO; HAY, DAVID C
To: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
Reel/Frame 025010/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2009
From: MAJUMDAR, ANISH SEN
To: GERON CORPORATION
Reel/Frame 022554/0883 →
Continuity (2)
Provisional Application 60810416 · Jun 2, 2006
Related Publication 20100086999A1 · Apr 8, 2010